Nimbus Discovery Presents Preclinical Data on Highly Selective IRAK4 Inhibitors for the Treatment of Rheumatic Diseases
Published: Nov 12, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, will present data today at the American College of Rheumatology (ACR) Annual Scientific Meeting in Washington, D.C., demonstrating robust efficacy and selectivity of their IRAK4-inhibitors in preclinical models of rheumatic and auto-immune diseases. IRAK4, is a kinase protein, well-validated and long sought after as a target for the treatment of such conditions as lupus, rheumatoid arthritis, psoriasis and inflammatory bowel disease. Previous attempts to identify small molecule modulators of IRAK4 have failed, and yet, the Nimbus compounds show good drug-like properties and are candidates for further development with the potential to make a significant positive impact on patients.